MacroGenics, Inc.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company that develops innovative antibody-based therapeutics for cancer treatment. The company generates its product candidates from proprietary antibody technology platforms, including antibody-drug conjugates (ADCs) and multi-specific antibodies, referred to as DART and TRIDENT molecules. This approach has led to three product candidates receiving marketing approval from the U.S. Food and Drug Administration (FDA). MacroGenics has also formed strategic collaborations with global biopharmaceutical companies, which have provided over $1.6 billion in non-dilutive funding since the company's inception in 2000. These collaborations also leverage additional expertise to advance partnered product candidates. MacroGenics operates a commercial-scale cGMP antibody manufacturing facility at its Maryland headquarters. This facility supports the company's clinical programs and provides outsourced contract development and manufacturing services to collaborators and other third parties for commercial and clinical products, helping to offset a significant portion of its operating costs. The company currently has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule targeting checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC targeting B7-H3 with a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; and MGC028, an ADC targeting ADAM9 with a novel TOP1i-based linker-payload. MacroGenics is also developing preclinical-stage ADC and next-generation T-cell engager programs.